Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Lilly

Weight loss from Lilly’s Zepbound drug reversed after stopping treatment, according to study

‘They gain back about half the weight they had originally lost over a one-year period of time,’ professor says

The Independent UK

Career advice from the CFOs of Dell, Eli Lilly, and Marriott—3 women who have each spent 20-plus years climbing the ladder at one company

As the CFO role continues to evolve, the leaders also explained the integral part of being an effective finance chief.

Fortune

Eli Lilly’s CFO explains why the company’s newest weight-loss drug Zepbound will cost 20% less than the current options

Zepbound is expected to be available in the U.S. by the end of the year.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA approves Zepbound, a new obesity drug that will take on Wegovy

Eli Lilly said the obesity medicine, which helped adults in clinical studies lose about 20% of their body weight, will be available in the U.S. by the end of the year. The list price will be $1,060.

WEKU

Novo Nordisk isn’t alone: Sales of Wegovy rival Mounjaro explode as drugmaker Eli Lilly profits from Americans’ weight-loss craze

Drugs helping weight-loss like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro drove blockbuster sales for the pharma giants in the third quarter.

Fortune

Prescribe to Profits With These 3 Pharma Stocks

The pharma industry looks well-positioned for solid growth in the long term amid the rising incidence of chronic illnesses and technological advancements. So, quality pharma stocks, Eli Lilly and Company (LLY), Merck & Co. (MRK), and Teva Pharmaceutical (TEVA) could be profitable investments. Read on.

StockNews.com

3 Pharma Stocks Smart Money Is Following in September

With the rising prevalence of chronic diseases, the demand for pharmaceutical products is anticipated to rise. Therefore, investors could consider buying three fundamentally robust pharma stocks, Eli Lilly and Company (LLY), Zoetis (ZTS), and Taro Pharmaceutical Industries (TARO), which are gaining traction among institutional investors this month. Learn more….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Chart of the Day: Eli Lilly (LLY) Edges to New Record High

The Barchart Chart of the Day belongs to Eli Lilly (LLY) . I found the stock by using Barchart.com to find the "Barchart New Highs" page, and then I clicked on pull-down to select stocks with new 52-week highs. I then viewed the stocks on the list with the FlipCharts...

Barchart

Soaring sales of diabetes drug Mounjaro, often used for weight loss, sends Eli Lilly to new heights

Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected

The Independent UK

Should Investors Start Watching Eli Lilly & Co. (LLY) This Week?

Despite macroeconomic headwinds dampening the growth of various industries, Eli Lilly and Company (LLY) has remained resilient and is ramping up investments in medical research. So, will it be a good watchlist addition this week? Keep reading.

StockNews.com

Lilly applies for Alzheimer’s drug’s US approval after trial success

Eli Lilly & Co. said it applied for full U.S. approval of its Alzheimer’s disease drug that’s expected to compete with Eisai Co.’s Leqembi as the U.S. drugmaker revealed details of a final-stage trial at a conference in Amsterdam.

Tribune News Service

Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concern

New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening

The Independent UK

Ozempic isn't alone. A whole class of 'revolutionary' weight-loss drugs is on the market—but only for the wealthy

“We're experiencing something here that is very, very different, very exciting from a healthcare perspective, and very expensive,” says Aon's Michael Manolakis.

Fortune

Revealed: pharma giants pour millions of pounds into NHS to boost drug sales

Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

Lisa Jarvis: Eli Lilly’s new weight-loss drug is even better than Ozempic

New data from an experimental drug being developed by Eli Lilly & Co. raises an intriguing question about obesity treatments: How low can the weight loss go?

StockNews.com

3 Stocks to Own as Alzheimer's Drugs Bring Relief

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

Fortune

Eli Lilly’s CEO pinpoints the 3-pronged problem big execs face with remote work

Managing a distributed workforce is “the leadership challenge of our decade,” David Ricks, CEO of pharma giant Eli Lilly, said.

The Conversation

Billions is spent on cancer research globally – but is it money well spent?

In 2020, 19 million people around the world received a cancer diagnosis. By 2040, that number is expected to reach 28 million. Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.

Get all your
news in one place.

100’s of premium titles.
One news app.

WEKU

Eli Lilly says an experimental drug slows Alzheimer's worsening

In the 18-month trial, people in the early stages of Alzheimer's who received infusions of donanemab showed 35% less decline in thinking skills compared to those given a dummy drug, Lilly announced.

Al Jazeera

‘Remarkable’ drug reduces Alzheimer’s decline, study shows

Experts say trial provides more evidence that targeting plaque proteins in brain can slow the disease’s progression.

The Guardian - UK

New Alzheimer’s drug slows cognitive decline by 35%, trial results show

Donanemab is second drug in a year to succeed in trials in what could be ‘beginning of the end’ of disease

The Independent UK

Eli Lilly says experimental drug slows Alzheimer's worsening

Eli Lilly and Co. says its experimental Alzheimer's drug appears to slow worsening of the mind-robbing disease

Daily Record

New weight loss drug helping people lose 2.5 stone is 'coming to the UK'

A weekly injection of tirzepatide has seen people with obesity and diabetes lose over 15 percent of their bodyweight.

The Independent UK

Weight loss jab that can help patients shed two-and-a-half stone set for UK approval

Tirzepatide could be given to patients with diabetes or heat disease

Businessweek

Good Luck Paying for Those $10,000 Obesity Drugs Everyone’s Talking About

Ozempic, Wegovy and Mounjaro can cause dramatic weight loss, and could create a market worth $150 billion a year.

1 … 9 10 11 12

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

125 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.